Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.61 |
| ▸ | JAK1 | P23458 | 18/20 | 0.61 |
| ▸ | JAK3 | P52333 | 7/20 | 0.50 |
| ▸ | TYK2 | P29597 | 4/20 | 0.50 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18975928 | 0.92 | JAK2 (0.60) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL18975872 | 0.92 | JAK2 (0.60) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL20527961 | 0.91 | JAK2 (0.61) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL20527938 | 0.89 | JAK2 (0.62) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL18975730 | 0.89 | JAK2 (0.62) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL18976302 | 0.89 | JAK2 (0.49) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL20527948 | 0.87 | JAK2 (0.60) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL18975965 | 0.87 | JAK2 (0.62) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL18975584 | 0.86 | JAK2 (0.68) | JAK2JAK1JAK3TYK2CIT | |
| SCHEMBL14563790 | 0.86 | JAK2 (0.45) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3360878-B9 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| EP-3360878-B1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2020-09-16 | — | — | EP | disclosed |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-05-14 | — | — | US | disclosed |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-05-14 | — | — | US | disclosed |
| US-10159662-B2 | Azetidine derivative, preparation method therefor, and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-12-25 | — | — | US | disclosed |
| US-20180289680-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-10-11 | — | — | US | disclosed |
| WO-2017097224-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045455-B2 | Azetidine derivative, preparation method therefor, and use thereof | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-20200147062-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-10159662-B2 | Azetidine derivative, preparation method therefor, and use thereof | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-20180289680-A1 | AZETIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.